Altre lingue IRRC Corporation

Azioni

7325

JP3105230001

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
724 ^JPY	-0,28%		-0,96%	+12,07%

2023	IRRC Corporation (TSE:7325) ha completato l'acquisizione della partecipazione dell'80,9% in Life Assist Co. Ltd. da Orix Life Insurance Corporation.	CI
2023	IRRC Corporation (TSE:7325) annuncia un riacquisto di azioni per 200.000 azioni, pari al 2,38% per 160 milioni di yen.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.	19/02
IRRC Corporation's Equity Buyback announced on August 18, 2023, has closed with 200,000 shares, representing 2.39% for ¥140.90 million.	16/02
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.	05/01
Henlius Biotech, Inc. - Results from Four Phase 1/2 Clinical Trials of Henlius Innovative Products Released at 2023 ESMO Asia	05/12
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.	03/10/23
IRRC Corporation completed the acquisition of 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation.	01/10/23
IRRC Corporation announces an Equity Buyback for 200,000 shares, for ¥160 million.	18/08/23
IRRC Corporation authorizes a Buyback Plan.	18/08/23
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.	16/08/23
IRRC Corporation's Equity Buyback announced on February 14, 2023, has closed with 300,300 shares, representing 3.48% for ¥228.63 million.	14/08/23
IRRC Corporation signed a basic agreement to acquire a 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation for approximately ¥400 million.	14/08/23
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.	07/07/23
IRRC Corporation Reports Earnings Results for the Nine Months Ended March 31, 2023	15/05/23
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.	05/04/23
CStone Announces Publication of GEMSTONE-201 Study Results for Sugemalimab Monotherapy in the Treatment of Relapsed, Refractory Extranodal NK/T-Cell Lymphoma in Journal of Clinical Oncology	31/03/23
IRRC Corporation announces an Equity Buyback for 500,000 shares, representing 5.74% for ¥400 million.	14/02/23
IRRC Corporation authorizes a Buyback Plan.	14/02/23
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan	21/11/22
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022	06/06/22
IRRC : Pennsylvania Takes Next Step Toward Cap-and-Trade Amid Resistance	30/07/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue IRRC Corporation

Azioni

7325

JP3105230001

Altre lingue

Filtri